JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
JMP证券维持Protagonist Therapeutics的市场跑赢大盘，将目标股价上调至45美元
JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $42 to $45.
JMP证券分析师乔纳森·沃勒本维持Protagonist Therapeutics（纳斯达克股票代码：PTGX）的市场表现跑赢大盘，并将目标股价从42美元上调至45美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。